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Flow diverters have become an important tool in the man-agement of intracranial aneurysms.1–4 The pipeline embo-
lization device (PED) is a flow diverter that has received 
significant attention in the recent literature.2,3,5 The device 
was approved by the Food and Drug Administration (FDA) in 
2011 for treatment of large and giant wide-necked aneurysms 
arising from the cavernous segment to the superior hypophy-
seal segment of the internal carotid artery. In most series, flow 
diverters including the PED were used for the treatment of 
complex aneurysms not amenable to conventional endovas-
cular techniques, such as large and giant aneurysms, wide-
necked aneurysms and fusiform aneurysms.6–10 Whether the 
indications for flow diversion can be expanded to small aneu-
rysms in which conventional endovascular techniques are usu-
ally safe and effective remains uncertain.
Stent-assisted coiling is now a well-established technique 
for the treatment of intracranial aneurysms with an excellent 
safety–efficacy profile.11,12 Studies have assessed the safety and 
efficacy of the PED unilaterally without comparison with a 
control group treated with coiling or stent-assisted coiling.7,13–16 
These studies also included a heterogeneous population of 
patients (small versus large, ruptured versus unruptured, fusi-
form versus saccular, anterior circulation versus vertebrobasi-
lar aneurysms), which precluded any confident conclusion as 
to the safety profile of flow diverters in specific subgroups of 
patients. We present the results of the first study comparing 
PED and stent-assisted coiling in patients with unruptured, 
small (<10 mm) saccular aneurysms.
Methods
The University Institutional Review Board approved the study proto-
col. Forty consecutive patients with unruptured, previously untreated, 
small (<10 mm) aneurysms treated with PED (2011–2013) at our in-
stitution were identified from a prospectively maintained database. 
Patients treated with PED and adjunctive coiling were not included in 
the analysis. Every patient treated with the PED was matched to 4 con-
trol patients treated with stent-assisted coiling (2004–2011) based on 
patient age, sex, aneurysm location, and aneurysm size. Patients were 
excluded from this study if the aneurysm had previously ruptured, was 
located in the posterior circulation, or was fusiform in morphology.
Patients undergoing PED therapy received 75 mg/d of clopidogrel 
and 81 mg/d of aspirin for 10 days before the intervention. Platelet 
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function tests were routinely performed using aspirin assay and P2Y12 
assay (VerifyNow; Accumetrics, San Diego, CA) to ascertain that the 
level of platelet inhibition was between 30% and 90%. Patients with in-
hibition <30% were reloaded and the assay rechecked. Poor responders 
to clopidogrel were then switched to prasugrel (brand name Effient, Eli 
Lilly and Company, Indianapolis, IN). Patients with inhibition >90% 
were admitted to the hospital, their procedure was canceled, and Plavix 
was held until platelet inhibition level fell <90%. An initial 100 U/kg 
of heparin bolus was administered and activated clotting time was 
maintained at 2× the patient’s baseline intraoperatively. Heparin was 
discontinued but not reversed at the conclusion of the procedure. Dual 
antiplatelet therapy was continued for ≥6 months after the procedure. 
Procedures were performed under general endotracheal anesthesia and 
continuous neurophysiologic monitoring, including electroencepha-
lography and somatosensory-evoked potentials. PEDs were deployed 
through a Marksman microcatheter (ev3, Irvine, CA) using a triaxial 
guide-catheter system. The number of stents deployed was left to the 
operator’s discretion but, in general, when stasis was seen in the aneu-
rysm dome no further devices were deployed. Recently, we have been 
using only a single device for most aneurysms. The expansion of the 
PED was documented under fluoroscopy or with additional DynaCT/
Xpert CT angiography at the operator’s discretion. Inadequate vessel 
wall apposition was remedied with Gateway balloon (Boston Scientific, 
Fremont, CA) angioplasty when needed. Placement of additional PEDs 
was considered at follow-up if the aneurysm remained unchanged or 
did not sufficiently decrease in size, despite treatment.
Our protocol and technique for stent-assisted coiling have been de-
tailed previously.11 Briefly, when the use of a stent was anticipated, 
patients were pretreated with daily 81 mg of aspirin and 75 mg of clopi-
dogrel for 10 days before the procedure. Dual antiplatelet therapy was 
continued for 2 months after the intervention. Coiling was interrupted 
when the aneurysm was completely occluded or when no additional 
coils could be deployed. Stent-assisted coiling was typically performed 
using the microcatheter jailing technique in which the stent is deployed 
after the aneurysm is microcatheterized but before coil deployment.
The outcomes of 40 PED patients and 160 stent-coil patients 
matched for patient age, sex, aneurysm location, and aneurysm size 
were compared. Medical charts were reviewed retrospectively to de-
termine patient demographics, aneurysm characteristics, procedural 
specifics, and procedural complications. Only procedural complica-
tions with clinical repercussions are reported. Angiographic follow-up 
(digital subtraction angiography or magnetic resonance angiography) 
was scheduled at 3 to 6 months, 1 year, 2 years, and 5 years after 
treatment. Aneurysm obliteration rates were determined as percent-
ages and transformed into a dichotomic variable: complete oblitera-
tion (100%) and incomplete obliteration (<100%). Regardless of the 
need for further intervention, any filling at the neck or the dome of the 
aneurysm was considered <100% occlusion and classified as incom-
plete obliteration. Clinical outcomes at the last available follow-up 
were collected from follow-up notes of the attending physician and 
classified using the modified Rankin Scale (mRS).
Statistical Analysis
Data are presented as mean and range for continuous variables and as 
frequency for categorical variables. Matched analysis was performed 
as appropriate. Univariate conditional (matched) analysis was used 
to test covariates predictive of the following dependent variables: 
treatment complications, follow-up obliteration, and clinical outcome 
(mRS, 0–2 versus 3–6 and mRS, 0–1 versus 2–6). Interaction and con-
founding were assessed through stratification and relevant expansion 
covariates. Factors predictive in univariate analysis (P<0.20)17 were 
entered into a multivariate conditional logistic regression analysis. P 
values of ≤0.05 were considered statistically significant. Statistical 
analysis was performed with Stata 10.0 (College Station, TX).
Results
Baseline Characteristics
Mean patient age was similar in the PED group (52.1±13.7 
years) and the stent-coil group (52.6±11.4 years; P=0.8). The 
proportion of female patients was 85% in both groups. Mean 
aneurysm size was 6.2±2.4 mm in the PED group and 6.0±1.6 
mm in the stent-coil group (P=0.3). The proportion of aneu-
rysms >6 mm was similar in PED (60%) and stent-coil patients 
(57%; P=0.8). Aneurysm locations (Table 1) were matched 
between the 2 groups.
Aneurysm Treatment
PED deployment was successful in all 40 patients. The num-
ber of PEDs used was 1.3±0.4 per aneurysm. A single PED 
was used in 26 (65%) aneurysms and 2 PEDs in 14 (35%) 
aneurysms. Balloon angioplasty was performed for optimal 
PED expansion in 1 (2.5%) patient.
In the stent-coil group (n=160), initial Raymond scores 
were I (complete occlusion) in 71 (44%) patients, II (resid-
ual neck) in 56 (35%) patients, and III (dome filling) in 33 
(20.6%) patients.
Procedural Complications
Procedure-related complications occurred in 2 (5%) patients 
(1 ischemic event and 1 distal hemorrhage) in the PED group 
versus 5 (3%) patients (4 ischemic events and intraopera-
tive rupture) in the stent-coil group (P=0.7). There was no 
procedure-related mortality in either group. No patient had 
a symptomatic side-branch occlusion after PED therapy. The 
following factors were tested for as predictors of complica-
tions: age, sex, aneurysm location, aneurysm size, aneurysm 
morphology, and type of treatment. In univariate analysis, 
older age (≥65 years; odds ratio [OR], 3.7; 95% confidence 
interval [CI], 0.8–17.7; P=0.09) predicted procedural compli-
cations. In multivariate analysis, there was a trend for older 
age (≥65 years) to predict complications (OR, 3.8; 95% CI, 
0.7–17.7; P=0.09). The type of treatment was not a predictor 
of complications even after controlling for age.
Angiographic Outcome
Angiographic follow-up was available for 39 (97.5%) patients 
treated with PED and 147 (92%) patients treated with stent-
assisted coiling. Median angiographic follow-up time was 
7 months in the PED group and 15 months in the stent-coil 
group (P<0.001). At the latest follow-up, a higher proportion 
of aneurysms treated with PED (80%; n=31) achieved com-
plete obliteration (100%) compared with coiled aneurysms 
(70%; n=103) but the difference fell short of statistical sig-
nificance (P=0.2; Table 2). In the stent-coil group (n=160), 
Raymond scores at the latest follow-up were I (complete 
occlusion) in 103 (70%) patients, II (residual neck) in 17 
(11.5%) patients, and III (dome filling) in 28 (19%) patients. 
Table 1. Aneurysm Locations
Aneurysm Location PED (%) Stent-Coil (%)
Carotid ophthalmic/paraclinoid 37 (92.5) 145 (90.7)
Carotid cavernous 1 (2.5) 5 (3.1)
Posterior communicating 1 (2.5) 5 (3.1)
Middle cerebral artery 1 (2.5) 5 (3.1)
Total 40 160
PED indicates pipeline embolization device.
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The following factors were tested for as predictors of occlu-
sion: age, sex, aneurysm location, aneurysm size, aneurysm 
morphology, type of treatment, complications, and follow-up 
time. In univariable analysis, factors predicting nonocclusion 
were increasing aneurysm size (OR, 1.23; 95% CI, 1.01–1.49; 
P=0.04) and carotid cavernous-posterior communicating 
artery-middle cerebral artery aneurysm location (ie, aneurysm 
locations with rates of complete occlusion <70%; P=0.01). In 
multivariable analysis, increasing aneurysm size (OR, 5; 95% 
CI, 1.4–14; P=0.01) and carotid cavernous-posterior commu-
nicating artery-middle cerebral artery aneurysm location (OR, 
5; 95% CI, 1.4–14; P=0.01) remained statistically significant 
independent predictors of nonocclusion.
Retreatment was necessary in 4 (10%) patients in the PED 
group and 13 (9%; P=0.8) patients in the coil group. It should 
be noted that retreatment was undertaken for recurrences in 
all 13 patients in the stent-coil group, whereas none of the 4 
patients in the PED group had a recurrence. In fact, aneurysm 
size decreased to some extent in 3 of the 4 PED patients but 
the decision was made to place additional devices to accelerate 
and increase the likelihood of further aneurysm thrombosis.
Clinical Outcome
Clinical follow-up was available for 39 (97.5%) patients in 
the PED group and 148 (93%) patients in the stent-coil group. 
Median follow-up time was 7 months in the PED group and 17 
months in the stent-coil group (P<0.001). The proportion of 
patients with mRS 0 to 2 was 100% (39/39) in the PED group 
and 98% in the stent-coil group (99%; 146/148; P=0.9). The 
proportion of patients with mRS 0 to 1 was 95% (37/39) in the 
PED group and 96% in the stent-coil group (96%; 142/148; 
P=0.9). The following factors were tested for as predictors of 
outcome: age, sex, aneurysm location, aneurysm size, aneu-
rysm morphology, type of treatment, and complications. In 
univariable analysis, increasing aneurysm size (OR, 5.9; 
95% CI, 0.6–5.2; P=0.1) predicted a poor clinical outcome 
(mRS>1). In multivariable analysis, no factor was a signifi-
cant predictor of poor clinical outcome.
Discussion
The only flow diverter currently approved by the FDA is the PED. 
Other flow diverters include Silk (Balt, Montmorency, France), 
Surpass (Stryker, Fremont, CA), and FRED (Microvention, 
Tustin, CA).18 The Silk stent has been extensively used outside 
the United States, and the Surpass has recently shown promis-
ing results in a small series from Europe.4,19,20
Initially reserved for complex, giant, and fusiform aneu-
rysms, flow diverters are currently increasingly used in the 
management of small and less complex aneurysms at some 
institutions. Many interventionalists, however, remain wary 
of this approach and continue to prefer traditional endovas-
cular strategies, especially for small aneurysms. A recent 
meta-analysis on flow diverters by Brinjikji et al,21 including 
1451 patients with 1654 aneurysms, found procedure-related 
morbidity and mortality rates of 5% and 4%, respectively. The 
authors concluded that the risk of procedure-related morbidity 
and mortality with flow diverters is not negligible and should 
be taken into account when considering the best therapeutic 
option for intracranial aneurysms. Another meta-analysis of 
15 studies that compiled 897 patients with 1018 aneurysms 
found an early mortality rate of 2.8%, a late mortality rate 
of 1.3%, and an overall neurological morbidity rate of 9.9%. 
The authors of the meta-analysis also found that available data 
supporting the use of flow diverters were heterogeneous and 
prone to publication biases, concluding that the use of flow 
diverters in patients eligible to more conventional treatments 
should be restricted to controlled clinical trials.
However, several studies have demonstrated convincingly 
that the PED carries a high safety and efficacy profile. In a large 
Turkish series of 191 patients treated with the PED, Saatci et al7 
reported a 6-month occlusion rate of 91% with an impressive 
permanent morbidity rate of only 1%. A recent well-designed 
multicenter international trial reported a success rate of 99%, 
an occlusion rate of 74%, and a major ipsilateral stroke or neu-
rological death rate of only 5.6%.7 Pistocchi et al2 treated 30 
aneurysms at and beyond the circle of Willis with flow diverters 
(Silk and Pipeline) reporting permanent neurological complica-
tion in only 3.7% and aneurysm occlusion in 82% of patients. 
Likewise, in an multicenter study of 143 patients with 178 aneu-
rysms from Hong Kong, Yu et al8 reported a complete aneurysm 
occlusion rate of 84%, an overall neurological complication 
rate of 8.4%, and a periprocedural death or major stroke rate 
of 4.2% (median follow-up of 18 months). They concluded that 
PED should be considered a first choice for treating unruptured 
aneurysms. All these studies included a heterogeneous popula-
tion of patients (no separate analysis was done for small aneu-
rysms) and did not put the results of flow diversion in direct 
comparison with those of conventional endovascular techniques 
especially stent-assisted coiling, which has shown an excellent 
safety–efficacy profile in several large studies.11,12,22,23
The present study is not the first to compare flow diverters 
with coiling. However, it is the first to specifically compare 
stent-assisted coiling with flow diversion, or even compare the 2 
techniques in small aneurysms. In a small study, Lanzino et al24 
compared 22 paraclinoid aneurysms treated with the PED with 
historic controls. The authors reported a significantly higher 
rate of complete occlusion in PED patients (76%) than coiled 
patients (21%) with a similar rate of morbidity and concluded 
that long-term follow-up was important to validate flow diver-
sion definitively as a superior therapeutic strategy for proximal 
internal carotid artery aneurysms. In a previous report, we have 
compared the periprocedural, angiographic, and clinical out-
comes of flow diversion and coiling in unruptured, large, and 
giant (≥10 mm) aneurysms.10 We have found a similar compli-
cation rate in both groups (7.5%) along with a higher aneurysm 
occlusion rate (86% versus 41%) and a lower retreatment rate 
with flow diversion (2.8% versus 37%). In multivariable analy-
sis, the odds of achieving occlusion of large aneurysms were 
Table 2. Rates of Aneurysm Occlusion
Complete Aneurysm Occlusion
≤6 mo 7 to 12 mo >12 mo
PED 21/27 (77%) 17/21 (81%)     6/8 (75%)
Stent-assisted 
coiling
21/30 (70%) 56/70 (80%) 40/53 (75%)
PED indicates pipeline embolization device.
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>10× higher with flow diversion than with coiling. These results 
led us to conclude that flow diverters were a preferred option 
for large and giant aneurysms. In the present study, we sought 
to determine whether flow diversion is also a better strategy for 
small aneurysms (<10 mm), a subgroup in which stent-assisted 
coiling has traditionally generated favorable clinical and angio-
graphic results. We found that flow diversion can be undertaken 
with no additional morbidity and similar clinical outcomes com-
pared with stent-assisted coiling. There was also a trend toward 
higher occlusion rates with the PED (80% versus 70%), but the 
study was likely underpowered to detect small differences in 
angiographic outcomes between 2 highly efficient endovascular 
techniques. Although retreatment rates did not differ between 
the 2 groups, retreatment was always undertaken for a recur-
rence in stent-coiled patients, whereas in PED patients retreat-
ment was undertaken because the aneurysm had not sufficiently 
decreased in size. We have also recently found that PED treat-
ment requires significantly shorter fluoroscopy and procedure 
times compared with stent-assisted coiling.25 Moreover, a 
recent study has demonstrated that PED embolization is more 
economical than stent-assisted coiling with a 27% reduction 
in the cost per millimeter of aneurysm treated,26 although any 
cost benefit will also depend on aneurysm volume, coil type, 
and number of PEDs used.27 Taken together, these data suggest 
that the indications of flow diversion can be safely extended 
to unruptured, small aneurysms (<10 mm). Some may argue, 
however, that stent-assisted coiling is a better option than flow 
diversion because of the higher immediate complete occlusion 
rate and the shorter period of dual antiplatelet therapy.
In the present study, the initial occlusion rate (Raymond 
score I, ie, 100% occlusion) with stent-assisted coiling was 
48% increasing to 70% at follow-up. These rates are consis-
tent with those reported in the literature. In a large study of 
500 stent-coiled aneurysms by Geyik et al,23 complete occlu-
sion was achieved in 42.2% of the aneurysms initially, and the 
rate progressed to 90.8% at follow-up. Likewise, a systematic 
review of the literature on stent-assisted coiling by Shapiro et 
al28 reported a 45% complete occlusion rate initially, increas-
ing to 61% at follow-up. The morbidity rates with stent-
assisted coiling in our study are largely in line with previously 
reported series. Lessne et al29 reported a 5.4% rate of throm-
boembolic events, whereas Maldonado et al30 reported a 2.9% 
combined morbidity–mortality rate after stent-assisted coiling 
of 76 aneurysms. Likewise, in the multicenter Enterprise reg-
istry, procedural data demonstrated a 6% temporary morbid-
ity, 2.8% permanent morbidity, and 2% mortality.31
Although the complications of stent-assisted coiling are 
essentially limited to thromboembolic events and intrapro-
cedural aneurysm ruptures,11,12 flow diversion carries the 
additional risk of distal parenchymal hemorrhage, delayed 
migration of the device, and delayed aneurysm rupture.9,32–36 
Distal parenchymal hemorrhage may occur ipsilaterally or even 
contralaterally to the aneurysm and its mechanism may involve 
hemorrhagic conversion of ischemic lesions, embolized foreign 
material, loss of arterial autoregulation of the distal arteries, 
or dual antiplatelet therapy.5,37 Device migration is a recently 
recognized complication of flow diverters that is attributed to 
a mismatch in arterial diameter between inflow and outflow 
vessels. The migration may occur proximally or distally and 
may lead to devastating complications, such as aneurysm rup-
ture or thromboembolic events.32 Delayed aneurysm rupture is 
a dreaded complication of flow diversion that typically occurs 
in large and giant aneurysms. Its cause remains uncertain but 
may involve altered hemodynamics and enzymatic degradation 
of the aneurysm wall from thrombus formation. The complica-
tion rate in the present report was low with flow diversion and 
did not differ significantly from that of stent-assisted coiling. 
Finally, if PED therapy is not effective in achieving complete 
aneurysm obliteration, endovascular access to the aneurysm 
will have been permanently lost and the only options available 
for further treatment would be reduced to open surgery or addi-
tional placement of PEDs. Also, clip application for proximal 
control is possible only proximal to the PED because the device 
is irreversibly deformed by clip application.38
Limitations
This study is retrospective in design and reflects the experience 
of a single center. We could not provide occlusion rates at stan-
dard time points. Instead, we have compared aneurysm occlu-
sion rates at the latest follow-up. Although the 2 groups were 
well matched with regard to baseline characteristics, the clinical 
and angiographic follow-up time differed significantly. As such, 
the occlusion rate with PED would have been even higher if 
patients were followed up for longer periods, which further sup-
ports the efficacy of flow diverters.8,14 Improved endovascular 
technology and increasing operator experience with aneurysm 
embolization techniques could have favored the PED group. The 
retreatment rate with the PED is closely related to the number 
of devices deployed during the initial embolization procedure. 
Because we tend to use only a single device in most cases (with 
placement of further devices only if the aneurysm remains 
open at follow-up), the PED retreatment rate would have been 
even lower had we adopted a different strategy where multiple 
devices are deployed initially. Despite these limitations, this 
study is the first to provide a comparative analysis of clinical and 
angiographic outcomes in small aneurysms treated with PED 
and stent-assisted coiling. Randomized controlled trials com-
paring flow diversion and conventional endovascular techniques 
are currently underway. The Flow Diversion in Intracranial 
Aneurysm Treatment (FIAT) trial39 is a randomized open label 
trial comparing flow diversion with best standard treatment in 
the management of difficult intracranial aneurysms. The trial is 
sponsored by the Center hospitalier de l’Université de Montréal 
and is currently recruiting participants. The LARGE aneurysm 
randomized trial40 is an ongoing prospective, randomized, study 
comparing coil embolization versus flow diversion in large (>10 
mm), anterior circulation intracranial aneurysms sponsored by 
the Medical University of South Carolina. Another trial is also 
taking place in France and compares the 2 techniques in unrup-
tured saccular wide-neck intracranial aneurysms >7 mm.41
Conclusions
Both flow diversion and stent-assisted coiling are safe and highly 
effective techniques for treatment of unruptured, small saccular 
aneurysms of the anterior circulation. The PED was associated 
with similar aneurysm occlusion rates, periprocedural morbid-
ity, and short-term clinical outcomes. These findings suggest 
that the indications of the PED can be safely extended to small 
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intracranial aneurysms that are amenable to conventional endo-
vascular techniques. Larger studies and long-term follow-up are 
necessary to determine the optimal treatment that leads to the 
highest rate of obliteration and best clinical outcomes.
Disclosures
None.
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